Empresa Brasileira de Hemoderivados e Biotecnologia (Hemobras), Baxter sales and marketing update

Brazilian state company Hemobras granted Baxter the exclusive right to become Brazil's provider of recombinant factor VIII ( rFVIII) to treat hemophilia A over the next 20 years. Baxter will receive p...